326 related articles for article (PubMed ID: 10720289)
1. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
Rice GP; Filippi M; Comi G
Neurology; 2000 Mar; 54(5):1145-55. PubMed ID: 10720289
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. Whole brain volume changes in patients with progressive MS treated with cladribine.
Filippi M; Rovaris M; Iannucci G; Mennea S; Sormani MP; Comi G
Neurology; 2000 Dec; 55(11):1714-8. PubMed ID: 11113227
[TBL] [Abstract][Full Text] [Related]
4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
6. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
7. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
8. The treatment of chronic progressive multiple sclerosis with cladribine.
Beutler E; Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1716-20. PubMed ID: 8643695
[TBL] [Abstract][Full Text] [Related]
9. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Comi G; Cook SD; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett AC; Viglietta V; Greenberg SJ
J Neurol; 2013 Apr; 260(4):1136-46. PubMed ID: 23263473
[TBL] [Abstract][Full Text] [Related]
10. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
Leist TP; Vermersch P
Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
[TBL] [Abstract][Full Text] [Related]
11. Cladribine in treatment of chronic progressive multiple sclerosis.
Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
Lancet; 1994 Jul; 344(8914):9-13. PubMed ID: 7912347
[TBL] [Abstract][Full Text] [Related]
12. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
[TBL] [Abstract][Full Text] [Related]
13. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
[TBL] [Abstract][Full Text] [Related]
14. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis DM; Meiner Z; Lehmann D; Gomori JM; Schwarz A; Linde A; Abramsky O
Neurology; 1996 Aug; 47(2):341-6. PubMed ID: 8757002
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
16. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
[TBL] [Abstract][Full Text] [Related]
17. A comparison of two neurologic scoring instruments for multiple sclerosis.
Koziol JA; Frutos A; Sipe JC; Romine JS; Beutler E
J Neurol; 1996 Mar; 243(3):209-13. PubMed ID: 8936349
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis.
Alshamrani F; Alnajashi H; Almuaigel MF
Cureus; 2020 Feb; 12(2):e6995. PubMed ID: 32206459
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
Selby R; Brandwein J; O'Connor P
Can J Neurol Sci; 1998 Nov; 25(4):295-9. PubMed ID: 9827230
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E
Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
